192 related articles for article (PubMed ID: 27481313)
1. Erythropoietin treatment in murine multiple myeloma: immune gain and bone loss.
Deshet-Unger N; Hiram-Bab S; Haim-Ohana Y; Mittelman M; Gabet Y; Neumann D
Sci Rep; 2016 Aug; 6():30998. PubMed ID: 27481313
[TBL] [Abstract][Full Text] [Related]
2. Erythropoietin is involved in the angiogenic potential of bone marrow macrophages in multiple myeloma.
De Luisi A; Binetti L; Ria R; Ruggieri S; Berardi S; Catacchio I; Racanelli V; Pavone V; Rossini B; Vacca A; Ribatti D
Angiogenesis; 2013 Oct; 16(4):963-73. PubMed ID: 23881169
[TBL] [Abstract][Full Text] [Related]
3. Macrophages as novel target cells for erythropoietin.
Lifshitz L; Tabak G; Gassmann M; Mittelman M; Neumann D
Haematologica; 2010 Nov; 95(11):1823-31. PubMed ID: 20595096
[TBL] [Abstract][Full Text] [Related]
4. Erythropoietin directly stimulates osteoclast precursors and induces bone loss.
Hiram-Bab S; Liron T; Deshet-Unger N; Mittelman M; Gassmann M; Rauner M; Franke K; Wielockx B; Neumann D; Gabet Y
FASEB J; 2015 May; 29(5):1890-900. PubMed ID: 25630969
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietin enhances immune responses in mice.
Katz O; Gil L; Lifshitz L; Prutchi-Sagiv S; Gassmann M; Mittelman M; Neumann D
Eur J Immunol; 2007 Jun; 37(6):1584-93. PubMed ID: 17458859
[TBL] [Abstract][Full Text] [Related]
6. Erythropoietin (EPO)-receptor signaling induces cell death of primary myeloma cells in vitro.
Våtsveen TK; Sponaas AM; Tian E; Zhang Q; Misund K; Sundan A; Børset M; Waage A; Brede G
J Hematol Oncol; 2016 Aug; 9(1):75. PubMed ID: 27581518
[TBL] [Abstract][Full Text] [Related]
7. Erythropoietin receptor in B cells plays a role in bone remodeling in mice.
Deshet-Unger N; Kolomansky A; Ben-Califa N; Hiram-Bab S; Gilboa D; Liron T; Ibrahim M; Awida Z; Gorodov A; Oster HS; Mittelman M; Rauner M; Wielockx B; Gabet Y; Neumann D
Theranostics; 2020; 10(19):8744-8756. PubMed ID: 32754275
[TBL] [Abstract][Full Text] [Related]
8. Erythropoietin Mediated Bone Loss in Mice Is Dose-Dependent and Mostly Irreversible.
Kolomansky A; Hiram-Bab S; Ben-Califa N; Liron T; Deshet-Unger N; Mittelman M; Oster HS; Rauner M; Wielockx B; Neumann D; Gabet Y
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32471308
[TBL] [Abstract][Full Text] [Related]
9. Erythropoiesis and erythropoietin in multiple myeloma.
Beguin Y
Leuk Lymphoma; 1995 Aug; 18(5-6):413-21. PubMed ID: 8528047
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic impact of erythropoietin-encapsulated liposomes targeted to bone marrow on renal anemia.
Miyazaki Y; Taguchi K; Sou K; Watanabe H; Ishima Y; Miyakawa T; Mitsuya H; Fukagawa M; Otagiri M; Maruyama T
Mol Pharm; 2014 Nov; 11(11):4238-48. PubMed ID: 25255196
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human erythropoietin and the anemia of multiple myeloma.
Barlogie B; Beck T
Stem Cells; 1993 Mar; 11(2):88-94. PubMed ID: 8457789
[TBL] [Abstract][Full Text] [Related]
12. Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models.
Mittelman M; Neumann D; Peled A; Kanter P; Haran-Ghera N
Proc Natl Acad Sci U S A; 2001 Apr; 98(9):5181-6. PubMed ID: 11309490
[TBL] [Abstract][Full Text] [Related]
13. Non-erythroid activities of erythropoietin: Functional effects on murine dendritic cells.
Lifshitz L; Prutchi-Sagiv S; Avneon M; Gassmann M; Mittelman M; Neumann D
Mol Immunol; 2009 Feb; 46(4):713-21. PubMed ID: 19027957
[TBL] [Abstract][Full Text] [Related]
14. Erythropoietin enhances Kupffer cell number and activity in the challenged liver.
Gilboa D; Haim-Ohana Y; Deshet-Unger N; Ben-Califa N; Hiram-Bab S; Reuveni D; Zigmond E; Gassmann M; Gabet Y; Varol C; Neumann D
Sci Rep; 2017 Sep; 7(1):10379. PubMed ID: 28871174
[TBL] [Abstract][Full Text] [Related]
15. [Analysis of causes for anemia in patients with multiple myeloma].
Rokicka-Piotrowicz M; Paszkowska M; Król M; Król M; Kuratowska Z
Pol Arch Med Wewn; 2000 Dec; 104(6):843-51. PubMed ID: 11424663
[TBL] [Abstract][Full Text] [Related]
16. Erythropoietin has an anti-myeloma effect - a hypothesis based on a clinical observation supported by animal studies.
Mittelman M; Zeidman A; Kanter P; Katz O; Oster H; Rund D; Neumann D
Eur J Haematol; 2004 Mar; 72(3):155-65. PubMed ID: 14962233
[TBL] [Abstract][Full Text] [Related]
17. Heart failure-associated anemia: bone marrow dysfunction and response to erythropoietin.
Ruifrok WP; Qian C; Silljé HH; van Goor H; van Veldhuisen DJ; van Gilst WH; de Boer RA
J Mol Med (Berl); 2011 Apr; 89(4):377-87. PubMed ID: 21191566
[TBL] [Abstract][Full Text] [Related]
18. The role of the blood island during normal and 5-fluorouracil-perturbed hemopoiesis.
Vogt C; Noé G; Rich IN
Blood Cells; 1991; 17(1):105-21; discussion 121-5. PubMed ID: 2018848
[TBL] [Abstract][Full Text] [Related]
19. Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration.
Oster W; Herrmann F; Gamm H; Zeile G; Lindemann A; Müller G; Brune T; Kraemer HP; Mertelsmann R
J Clin Oncol; 1990 Jun; 8(6):956-62. PubMed ID: 2189957
[TBL] [Abstract][Full Text] [Related]
20. [Erythropoietin in the pathogenesis of anemia in patients with multiple myeloma].
Rokicka-Piotrowicz M; Paluszewska M; Paszkowska M; Rakowska A; Wierzbicka E; Buras A; Kuratowska Z
Pol Arch Med Wewn; 1998 Mar; 99(3):218-23. PubMed ID: 9760808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
